title: Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study.
abstract: BACKGROUND
  Carperitide is used to treat acute decompensated heart failure (ADHF), but its effects on long-term prognosis have not been studied.
  
  
  RESULTS
  A multicenter randomized controlled study of 49 patients with ADHF was performed to clarify the drug's effects on long-term prognosis. Low-dose carperitide (0.01-0.05 microg x kg(-1 ) x min(-1)) was infused for 72 h as the initial treatment (n=26), whereas in the control group (n=23), standard medical treatment other than carperitide was given without limitation. Anti-aldosterone drugs were prohibited in both groups. During carperitide infusion, significant increases of the atrial natriuretic peptide and cyclic GMP levels and a significant decrease in the heart-type fatty acid-binding protein/serum creatinine ratio were observed, suggesting inhibition of myocyte cell membrane damage. On the other hand, no significant differences in the plasma brain natriuretic peptide, troponin T, and creatinine levels were noted in either group. During 18-month follow-up, significant reductions of death and rehospitalization occurred in the carperitide vs control group (11.5% vs 34.8%; p=0.0359). Cox regression analysis revealed that randomization to carperitide (p=0.020), pretreatment systolic blood pressure >or=140 mmHg (p=0.043), and beta-blocker therapy (p=0.016) were independent predictors for freedom from cardiac events.
  
  
  CONCLUSIONS
  Acute-phase low-dose carperitide infusion improved the long-term prognosis of patients with ADHF.
authors.affiliation: Department of Intensive Care Unit, Chiba-Hokusoh Hospital, Nippon Medical School, Inba-gun, Chiba, Japan.
authors.forename: Noritake
authors.initials: N
authors.lastname: Hata
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Seino
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Tsutamoto
authors.forename: Shinya
authors.initials: S
authors.lastname: Hiramitsu
authors.forename: Noboru
authors.initials: N
authors.lastname: Kaneko
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yokoyama
authors.forename: Keiji
authors.initials: K
authors.lastname: Tanaka
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Mizuno
authors.forename: Jun
authors.initials: J
authors.lastname: Nejima
authors.forename: Masahiko
authors.initials: M
authors.lastname: Kinoshita
mesh_terms: D000368:Aged; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage* / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D006152:Cyclic GMP / Q000097:blood; D050556:Fatty Acid-Binding Proteins / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D011379:Prognosis; D012074:Remission Induction; D020107:Troponin T / Q000097:blood
chemical_list: D050556:Fatty Acid-Binding Proteins; C472955:NPPA protein, human; D020107:Troponin T; D020097:Natriuretic Peptide, Brain; D009320:Atrial Natriuretic Factor; D003404:Creatinine; D006152:Cyclic GMP